The long-term impact of mTOR inhibition on cardiovascular risk is unclear, as findings of reduced cardiovascular risk in patients on mTOR inhibitors are confounded by more frequent use of lipid lowering therapy in response to dyslipidemia (65, 66). Here, MTOR is linked to metabolic syndrome.